![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
732kB | |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supplementary Material)
59kB |
| Item Type: | Article |
|---|---|
| Title: | Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network |
| Creators Name: | Greinix, H.T. and Attarbaschi, A. and Girschikofsky, M. and Greil, R. and Holter, W. and Neumeister, P. and Peters, C. and Petzer, A. and Rudzki, J. and Schlenke, P. and Schmitt, C.A. and Schwinger, W. and Wolf, D. and Worel, N. and Jaeger, U. |
| Abstract: | Chimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasting B cell aplasia. Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers. |
| Keywords: | CAR-T Cells, Position Statement, Network, Patient Selection Criteria, Infrastructure Requirements |
| Source: | memo: Magazine of European Medical Oncology |
| ISSN: | 1865-5041 |
| Publisher: | Springer |
| Volume: | 13 |
| Number: | 1 |
| Page Range: | 27-31 |
| Date: | March 2020 |
| Official Publication: | https://doi.org/10.1007/s12254-020-00582-4 |
Repository Staff Only: item control page
Download Statistics
Download Statistics
